Skip to main content

Table 3 Time to progression of liver lesions and overall survival

From: Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response

 

Number of patients

Median overall survival (days (95 % CI))

Median PFS liver (days (95 % CI))

p value (OS and PFS)

EHD at baseline

 Yes

12

200 (164–236)

83 (0–179)

0.081

 No

30

302 (216–388)

108 (79–137)*

0.007

Metastases

 Synchronous

32

255 (151–359)

92 (82–102)

0.266

 Metachronous

10

286 (60–512)

92 (88–96)

0.811

Bevacizumab treatment

 Yes

25

322 (247–397)

108 (75–141)

0.049

 No

17

215 (180–250)*

92 (87–97)

0.614

kRAS status

 Wild type

17

302 (244–360)

108 (51–165)

0.074

 Mutation

9

166 (75–257)

87 (0–187)

0.05a

 Unknown

16

282 (93–470)

92 (91–93)

 

Previous liver treatment

 Yes

12

286 (142–430)

86 (59–113)

0.840

 No

30

255 (148–362)

92 (91–94)

0.674

Baseline serum level

 Alkaline phosphatase

  Elevated

34

249 (159–339)

274 (134–335)

0.048

  Normal

8

355 (345–365)*

92 (90–94)*

0.021

 Albumin

  Decreased

11

166 (94–238)

90 (72–108)

0.003

  Normal

31

351 (263–439)*

92 (91–93)

0.078

Treatment setting

 Salvage setting

25

215 (137–293)

92 (86–98)

0.030

 Non-salvage setting

17

358 (347–369)*

120 (43–197)

0.070

Liver response at 1 month

 CR, PR or SD

31

341 (224–458)

0.003

 PD

10b

160 (122–198)*

  1. Non-salvage setting: patient declines (further) systemic treatment or systemic treatment must be stopped due to toxicity
  2. *Significant difference, log rank test p < 0.05
  3. PFS progression free survival, EHD extrahepatic disease, PR partial response, SD stable disease, PD progressive disease
  4. aOne patient was not evaluated at 1-month follow-up but first at 3-month follow-up
  5. b p values only comparing wild-type and mutation groups, not for comparison with unknown kRAS status